Composition: Each film-coated tablet contains Sitagliptin 100 mg
Manufacturer: Alkem Laboratories Ltd.
Pack Size: 10 tablets

Description:

Sitasure 100 contains Sitagliptin, a selective Dipeptidyl Peptidase-4 (DPP-4) inhibitor used in the management of type 2 diabetes mellitus (T2DM).
By inhibiting the DPP-4 enzyme, Sitagliptin increases the levels of active incretin hormones (GLP-1 and GIP), which:

Stimulate insulin secretion in a glucose-dependent manner.

Suppress glucagon release, thereby reducing hepatic glucose output.

This dual action leads to improved glycemic control, targeting both fasting and postprandial blood glucose levels. Sitagliptin is weight-neutral and has a low risk of hypoglycemia, making it suitable for long-term diabetes management.

Warnings & Precautions:

Monitor renal function before initiation and periodically during therapy.

Rare cases of acute pancreatitis have been reported; discontinue if persistent, severe abdominal pain occurs.

Hypoglycemia may occur when combined with insulin or sulfonylureas — consider lowering their dose.

May rarely cause severe arthralgia or hypersensitivity reactions (angioedema, anaphylaxis).

Not a substitute for insulin therapy in insulin-dependent diabetes.

Adverse Effects:

Common: Nasopharyngitis, headache, upper respiratory infection

Less common: Dizziness, abdominal pain, mild hypoglycemia (with insulin or sulfonylureas)

Rare: Pancreatitis, hypersensitivity reactions, arthralgia, hepatic enzyme elevation

Storage:

Store below 25°C, protected from light, heat, and moisture.
Keep out of reach of children.